Business
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and
About this update from Xencor, Inc.
[{"type":"text","content":" MONROVIA, Calif.--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Washington, D.C., and virtually November 10-14, 2021.\n\nThe presentations will include updated clinical results from expansion cohorts in the Phase 1 study of vudalimab (XmAb®717), a selective PD-1 x CTLA-4 bispecific antibody, in patients with prostate cancer, renal cell carcinoma and other cancers without approved checkpoint therapies. New data from four preclinical-stage programs, including Xencor’s IL-12-Fc cytokine program, PD-L1 x CD28 bispecific antibody program, TGFβR2 bispecific antibody platform, and bispecific NK cell engager platform, will also be presented.\n\nPresentation Details\n\n\nAbstract 523, “Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors”\n\n\nAbstract 707, “IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents”\n\n\nAbstract 698, “PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors”\n\n\nAbstract 872, “PD1 x TGFbR2 and CD5 x TGFbR2 bispecifics selectively block TGFbR2 on target-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors”\n\n\nAbstract 787, “Natural Killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines”\n\n\nPosters will be available in the poster hall and virtually to registrants of the SITC Annual Meeting, beginning at 7:00 a.m. ET on Friday, November 12. In the poster hall, odd numbered posters will be displayed on Friday, November 12, and even numbered posters will be displayed on Saturday, November 13. Posters will be archived under \"Events & Presentations\" in the Investors section of the Company's website located at www.xencor.com.\n\nAbout Vudalimab (XmAb®717)\n\nVudalimab (XmAb®717) is an XmAb bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-se...